MedTrace Logo

Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers

NCT01159730 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2011-11-16

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of multiple doses of VB-201 administered for 4 weeks and its efficacy on biomarkers.

Conditions

  • Biomarker

Interventions

DRUG

VB-201 or Placebo

Sponsors & Collaborators

  • Vascular Biogenics Ltd. operating as VBL Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01159730 on ClinicalTrials.gov